Elutia (ELUT) Stock Price, News & Analysis

Company Overview

Elutia, Inc. is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions. Elutia’s platform may also have applications in acute respiratory distress and inflammatory diseases, and the company continues to explore partnerships to expand its pipeline and accelerate development timelines.

Founded in 2015 and headquartered in New Haven, Connecticut, Elutia serves the U.S. market and is pursuing collaborations to support international expansion. Its management team brings together expertise in biopharmaceutical research, clinical development, and regulatory affairs, with a shared focus on advancing innovative therapies toward regulatory approval and commercialization.

Key Stats

• Today's Range: $1.00 to $1.06
• 50-Day Range: $0.95 to $1.20
• 52-Week Range: $0.50 to $2.64
• Volume: 173,037 shs
• Average Volume: 95,818 shs
• Market Capitalization: $45.35 million
• P/E Ratio: 1.23
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Elutia Stock Analysis - MarketRank™

Elutia scored higher than 65% of companies evaluated by MarketBeat, and ranked 206th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Elutia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Elutia has a consensus price target of $6.00, representing about 466.0% upside from its current price of $1.06.

Amount of Analyst Coverage

Elutia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elutia is 1.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elutia is 1.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.50.

Price to Book Value per Share Ratio

Elutia has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.14% of the float of Elutia has been sold short.

Short Interest Ratio / Days to Cover

Elutia has a short interest ratio ("days to cover") of 0.41, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elutia has recently decreased by 69.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elutia does not currently pay a dividend.

Dividend Growth

Elutia does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for ELUT on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Elutia to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elutia insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.60% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/19/2026
• Next Earnings (Estimated): 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELUT
• CIK: 1708527
• Web: www.elutia.com
• Phone: 240-247-1170
• Fax: 510-307-9896
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Elutia: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +466.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.86
• Trailing P/E Ratio: 1.23
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $53.38 million
• Net Margins: 312.09%
• Pretax Margin: -136.52%
• Return on Equity: N/A
• Return on Assets: -53.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.05
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: $12.29 million
• Price / Sales: 3.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.65 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 42,780,000
• Free Float: 30,976,000
• Market Cap: $45.35 million
• Optionable: Not Optionable
• Beta: 0.80